Clinical trials: Asthma Patients
Asthma
Triple in Asthma Dose Finding
Primary objective The primary objective was to evaluate the efficacy of a free combination of CHF 5259 at 3 dose levels plus Foster® 100/6 μg in a pMDI by comparison with Foster® 100/6 μg in terms of forced expiratory volume in…
- Trial name
- Triskel (NCT02127866)
- Testing
- CHF 5259 plus Foster 100/6 µg, Foster 100/6 µg (four puffs BID)
- Where
- 44 sites in Bulgaria, Germany and 4 more
- Volunteers
- 211 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.
The purpose is to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in…
- Trial name
- NIMBUS (NCT01704495)
- Testing
- AZD5069
- Where
- 96 sites in Bulgaria, Canada and 11 more
- Volunteers
- 1,147 people
- Sponsor
- AstraZeneca
Allergic Asthma
Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)
In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood.
- Trial name
- ESPIRA (NCT02096237)
- Testing
- IgE adsorber
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Pulmonary Disease, Chronic Obstructive
A Prospective Cohort Study of Asthma and COPD Overlap in Japanese COPD Patients Using the Diagnostic Criteria of The Japanese Respiratory Society
This study is a multicentered and non-interventional prospective cohort study. Study centers shall be the institutions where the examinations, adopted in the ACO diagnostic criteria9) from The Japanese Respiratory Society, are…
- Trial name
- ACO-Registry (NCT03577795)
- Where
- Japan
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Asthma
Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting
TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G…
- Trial name
- TRIMAXIMIZE (NCT06100042)
- Testing
- BDP/FF/G
- Where
- Italy
- Volunteers
- 233 people
- Sponsor
- Chiesi Italia
Moderate to Severe Asthma
A Phase Ib Study of RC1416 Injection
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
- Trial name
- NCT06911866
- Testing
- RC1416
- Where
- 16 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Asthma
Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).
The purpose of this study is to evaluate the level of satisfaction experienced by asthma or chronic obstructive pulmonary disease (COPD) patients when using the Fluticasone/Salmeterol HFA Metered Dose Inhaler (MDI) with counter…
- Trial name
- NCT00404261
- Testing
- Fluticasone/Salmeterol HFA
- Where
- 4 sites in Australia
- Volunteers
- 132 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with persistent asthma.
- Trial name
- NCT00403637
- Testing
- indacaterol maleate
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis
Asthma
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting
Primary Objective: To describe dupilumab health-related quality of life (HRQoL) effectiveness at 52 weeks compared to baseline. Secondary Objectives: To describe dupilumab HRQoL effectiveness at 12 and 24 weeks compared to…
- Trial name
- PROVERB (NCT06018441)
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Sanofi
Asthma
Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients
This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of metered dose inhaler (MDI) of Albuterol (Treatment T)…
- Trial name
- NCT00635505
- Testing
- albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA)
- Where
- 42 sites in United States
- Volunteers
- 300 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Eosinophilic Asthma
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1.
- Trial name
- NCT05985694
- Testing
- AD17002
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Pulmonary Disease, Chronic Obstructive
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale.
- Trial name
- NCT00354666
- Testing
- GSK159797
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU), Allergic Asthma
ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar
ROLL'YN-OMA is a real-world study in patients receiving standard biologic therapies who have been in control and/or remission of their disease for at least 3 months and whose physician has independently decided, within the…
- Trial name
- ROLL'YN-OMA (NCT07425639)
- Testing
- Omalizumab
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Celltrion HealthCare France
Aspirin Exacerbated Respiratory Disease (AERD)
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study…
- Trial name
- NCT02216357
- Testing
- Ifetroban, Oral Capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cumberland Pharmaceuticals
Asthma
Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI
The aim of this clinical study is to compare the lung exposure of the contents of the trial drug after administration of the fixed combination between beclomethasone and formoterol delivered via the new Chiesi dry powder inhaler…
- Trial name
- NCT01349257
- Testing
- BDP/Formoterol
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Chronic Obstructive Pulmonary Disease
ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)
The aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the FSI-10 questionnaire
- Trial name
- ANASA (NCT01475045)
- Where
- 2 sites in Greece
- Volunteers
- 1,160 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Asthma
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
In both parts, the primary comparisons of interest are between the percentage of patients with drug-related adverse events at each dose and placebo during single and multiple dosing regimens.
- Trial name
- NCT03971539
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Boehringer Ingelheim
Asthma
TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing…
- Trial name
- Trimaximize PL (NCT06567977)
- Testing
- Trimbow
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Chiesi Poland Sp. z o.o.
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis